Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 2
2007 1
2010 2
2011 1
2013 2
2014 2
2015 5
2016 6
2017 7
2018 1
2019 4
2020 4
2021 3
2022 3
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.
Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, Sopp P, Norfo R, Rodriguez-Meira A, Ashley N, Jamieson L, Vyas P, Anderson K, Segerstolpe Å, Qian H, Olsson-Strömberg U, Mustjoki S, Sandberg R, Jacobsen SEW, Mead AJ. Giustacchini A, et al. Among authors: olsson stromberg u. Nat Med. 2017 Jun;23(6):692-702. doi: 10.1038/nm.4336. Epub 2017 May 15. Nat Med. 2017. PMID: 28504724 Free article.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators. Saussele S, et al. Among authors: olsson stromberg u. Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4. Lancet Oncol. 2018. PMID: 29735299 Clinical Trial.
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Dolinska M, Cai H, Månsson A, Shen J, Xiao P, Bouderlique T, Li X, Leonard E, Chang M, Gao Y, Medina JP, Kondo M, Sandhow L, Johansson AS, Deneberg S, Söderlund S, Jädersten M, Ungerstedt J, Tobiasson M, Östman A, Mustjoki S, Stenke L, Le Blanc K, Hellström-Lindberg E, Lehmann S, Ekblom M, Olsson-Strömberg U, Sigvardsson M, Qian H. Dolinska M, et al. Among authors: olsson stromberg u. Blood. 2023 Jul 6;142(1):73-89. doi: 10.1182/blood.2022016896. Blood. 2023. PMID: 37018663 Free PMC article.
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
Huuhtanen J, Adnan-Awad S, Theodoropoulos J, Forstén S, Warfvinge R, Dufva O, Bouhlal J, Dhapola P, Duàn H, Laajala E, Kasanen T, Klievink J, Ilander M, Jaatinen T, Olsson-Strömberg U, Hjorth-Hansen H, Burchert A, Karlsson G, Kreutzman A, Lähdesmäki H, Mustjoki S. Huuhtanen J, et al. Among authors: olsson stromberg u. Leukemia. 2024 Jan;38(1):109-125. doi: 10.1038/s41375-023-02074-w. Epub 2023 Nov 2. Leukemia. 2024. PMID: 37919606 Free PMC article.
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
Huuhtanen J, Ilander M, Yadav B, Dufva OM, Lähteenmäki H, Kasanen T, Klievink J, Olsson-Strömberg U, Stentoft J, Richter J, Koskenvesa P, Höglund M, Söderlund S, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Stenke L, Myhr-Eriksson K, Markevärn B, Lübking A, Dimitrijevic A, Udby L, Bjerrum OW, Hjorth-Hansen H, Mustjoki S. Huuhtanen J, et al. Among authors: olsson stromberg u. J Clin Invest. 2022 Sep 1;132(17):e152585. doi: 10.1172/JCI152585. J Clin Invest. 2022. PMID: 36047494 Free PMC article.
KIT signaling is dispensable for human mast cell progenitor development.
Dahlin JS, Ekoff M, Grootens J, Löf L, Amini RM, Hagberg H, Ungerstedt JS, Olsson-Strömberg U, Nilsson G. Dahlin JS, et al. Among authors: olsson stromberg u. Blood. 2017 Oct 19;130(16):1785-1794. doi: 10.1182/blood-2017-03-773374. Epub 2017 Aug 8. Blood. 2017. PMID: 28790106 Free PMC article.
The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study.
Dahlén T, Flygt H, Lübking A, Olsson-Strömberg U, Wennström L, Dreimane A, Själander A, Leach S, Gisslén M, Li H, Höglund M, Stenke L, Nyberg F. Dahlén T, et al. Among authors: olsson stromberg u. Leukemia. 2023 May;37(5):1156-1159. doi: 10.1038/s41375-023-01893-1. Epub 2023 Apr 10. Leukemia. 2023. PMID: 37037908 Free PMC article. No abstract available.
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators. Mahon FX, et al. Among authors: olsson stromberg u. J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647. Online ahead of print. J Clin Oncol. 2024. PMID: 38471049
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
Dahlén T, Edgren G, Ljungman P, Flygt H, Richter J, Olsson-Strömberg U, Wadenvik H, Dreimane A, Myhr-Eriksson K, Zhao J, Själander A, Höglund M, Stenke L. Dahlén T, et al. Among authors: olsson stromberg u. Am J Hematol. 2022 Apr;97(4):421-430. doi: 10.1002/ajh.26463. Epub 2022 Jan 20. Am J Hematol. 2022. PMID: 35015312 Free PMC article.
51 results